Recombinant human growth hormone in abstinent androgenic-anabolic steroid use: psychological, endocrine and trophic factor effects

Michael R. Graham, Bruce Davies, Andrew Kicman, David Cowan, David Hullin, Julien S. Baker

Research output: Contribution to journalArticle

Abstract

This study examined whether six days recombinant human growth hormone (rhGH) affected psychological profile in an abstinent androgenic-anabolic steroid (AAS) abusing group, compared with an abstinent AAS control group. Male subjects (n = 48) were assigned in a random fashion into one of two groups: (1): (n =24) control group (C); (2): (n =24) rhGH group (GH). A hospital anxiety scale (HADS) questionnaire was completed by all subjects. Physiological responses investigated included anthropometry. Biochemical markers examined included; serum glucose, sodium, urea, lipid profile, high sensitivity C-reactive protein (hsCRP), homocysteine (HCY), tetra-iodothyronine (T4), thyroid stimulating (TSH), luteinising (LH) and follicle stimulating (FSH) hormones, testosterone (T), prolactin (PRL), cortisol and insulin like growth factor-1 (IGF-I). HADS questionnaire significantly decreased in both anxiety (A) and depression (D) symptoms within GH (P < 0.017) and compared with C (P < 0.05). Body mass index (BMI) and fat-free mass index (FFMI) significantly increased (both P < 0.017) while body fat significantly decreased within GH (P < 0.017). IGF-I significantly increased within GH (P < 0.017) and significantly increased compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum HCY, hsCRP, TSH and T4, significantly decreased within GH (all P < 0.017). PRL significantly increased and T4 significantly decreased compared with C (both P < 0.05). The findings of this study suggest that short term use of rhGH has beneficial effects on mental state in individuals who were previous abusers of AAS and appeared to have a beneficial effect on cardiovascular risk markers associated with adverse mental health.
Original languageEnglish
Pages (from-to)9-18
Number of pages10
JournalCurrent Neurovascular Research
Volume4
Issue number1
DOIs
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Testosterone Congeners
Human Growth Hormone
Growth Hormone
Homocysteine
Psychology
Insulin-Like Growth Factor I
Prolactin
C-Reactive Protein
Anxiety
Sodium
Serum
Control Groups
Anthropometry
Follicle Stimulating Hormone
Somatomedins
Hydrocortisone
Urea
Testosterone
Adipose Tissue
Mental Health

Keywords

  • anxiety
  • body composition
  • cardiovascular
  • depression
  • psychology
  • insulin-like growth factor-I

Cite this

Graham, Michael R. ; Davies, Bruce ; Kicman, Andrew ; Cowan, David ; Hullin, David ; Baker, Julien S. / Recombinant human growth hormone in abstinent androgenic-anabolic steroid use : psychological, endocrine and trophic factor effects. In: Current Neurovascular Research. 2007 ; Vol. 4, No. 1. pp. 9-18.
@article{7791e1bb0274443ba6092743ce94c634,
title = "Recombinant human growth hormone in abstinent androgenic-anabolic steroid use: psychological, endocrine and trophic factor effects",
abstract = "This study examined whether six days recombinant human growth hormone (rhGH) affected psychological profile in an abstinent androgenic-anabolic steroid (AAS) abusing group, compared with an abstinent AAS control group. Male subjects (n = 48) were assigned in a random fashion into one of two groups: (1): (n =24) control group (C); (2): (n =24) rhGH group (GH). A hospital anxiety scale (HADS) questionnaire was completed by all subjects. Physiological responses investigated included anthropometry. Biochemical markers examined included; serum glucose, sodium, urea, lipid profile, high sensitivity C-reactive protein (hsCRP), homocysteine (HCY), tetra-iodothyronine (T4), thyroid stimulating (TSH), luteinising (LH) and follicle stimulating (FSH) hormones, testosterone (T), prolactin (PRL), cortisol and insulin like growth factor-1 (IGF-I). HADS questionnaire significantly decreased in both anxiety (A) and depression (D) symptoms within GH (P < 0.017) and compared with C (P < 0.05). Body mass index (BMI) and fat-free mass index (FFMI) significantly increased (both P < 0.017) while body fat significantly decreased within GH (P < 0.017). IGF-I significantly increased within GH (P < 0.017) and significantly increased compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum HCY, hsCRP, TSH and T4, significantly decreased within GH (all P < 0.017). PRL significantly increased and T4 significantly decreased compared with C (both P < 0.05). The findings of this study suggest that short term use of rhGH has beneficial effects on mental state in individuals who were previous abusers of AAS and appeared to have a beneficial effect on cardiovascular risk markers associated with adverse mental health.",
keywords = "anxiety, body composition, cardiovascular, depression, psychology, insulin-like growth factor-I",
author = "Graham, {Michael R.} and Bruce Davies and Andrew Kicman and David Cowan and David Hullin and Baker, {Julien S.}",
year = "2007",
doi = "10.2174/156720207779940699",
language = "English",
volume = "4",
pages = "9--18",
journal = "Current Neurovascular Research",
issn = "1567-2026",
publisher = "Bentham Science",
number = "1",

}

Recombinant human growth hormone in abstinent androgenic-anabolic steroid use : psychological, endocrine and trophic factor effects. / Graham, Michael R.; Davies, Bruce; Kicman, Andrew; Cowan, David; Hullin, David; Baker, Julien S.

In: Current Neurovascular Research, Vol. 4, No. 1, 2007, p. 9-18.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recombinant human growth hormone in abstinent androgenic-anabolic steroid use

T2 - psychological, endocrine and trophic factor effects

AU - Graham, Michael R.

AU - Davies, Bruce

AU - Kicman, Andrew

AU - Cowan, David

AU - Hullin, David

AU - Baker, Julien S.

PY - 2007

Y1 - 2007

N2 - This study examined whether six days recombinant human growth hormone (rhGH) affected psychological profile in an abstinent androgenic-anabolic steroid (AAS) abusing group, compared with an abstinent AAS control group. Male subjects (n = 48) were assigned in a random fashion into one of two groups: (1): (n =24) control group (C); (2): (n =24) rhGH group (GH). A hospital anxiety scale (HADS) questionnaire was completed by all subjects. Physiological responses investigated included anthropometry. Biochemical markers examined included; serum glucose, sodium, urea, lipid profile, high sensitivity C-reactive protein (hsCRP), homocysteine (HCY), tetra-iodothyronine (T4), thyroid stimulating (TSH), luteinising (LH) and follicle stimulating (FSH) hormones, testosterone (T), prolactin (PRL), cortisol and insulin like growth factor-1 (IGF-I). HADS questionnaire significantly decreased in both anxiety (A) and depression (D) symptoms within GH (P < 0.017) and compared with C (P < 0.05). Body mass index (BMI) and fat-free mass index (FFMI) significantly increased (both P < 0.017) while body fat significantly decreased within GH (P < 0.017). IGF-I significantly increased within GH (P < 0.017) and significantly increased compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum HCY, hsCRP, TSH and T4, significantly decreased within GH (all P < 0.017). PRL significantly increased and T4 significantly decreased compared with C (both P < 0.05). The findings of this study suggest that short term use of rhGH has beneficial effects on mental state in individuals who were previous abusers of AAS and appeared to have a beneficial effect on cardiovascular risk markers associated with adverse mental health.

AB - This study examined whether six days recombinant human growth hormone (rhGH) affected psychological profile in an abstinent androgenic-anabolic steroid (AAS) abusing group, compared with an abstinent AAS control group. Male subjects (n = 48) were assigned in a random fashion into one of two groups: (1): (n =24) control group (C); (2): (n =24) rhGH group (GH). A hospital anxiety scale (HADS) questionnaire was completed by all subjects. Physiological responses investigated included anthropometry. Biochemical markers examined included; serum glucose, sodium, urea, lipid profile, high sensitivity C-reactive protein (hsCRP), homocysteine (HCY), tetra-iodothyronine (T4), thyroid stimulating (TSH), luteinising (LH) and follicle stimulating (FSH) hormones, testosterone (T), prolactin (PRL), cortisol and insulin like growth factor-1 (IGF-I). HADS questionnaire significantly decreased in both anxiety (A) and depression (D) symptoms within GH (P < 0.017) and compared with C (P < 0.05). Body mass index (BMI) and fat-free mass index (FFMI) significantly increased (both P < 0.017) while body fat significantly decreased within GH (P < 0.017). IGF-I significantly increased within GH (P < 0.017) and significantly increased compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum HCY, hsCRP, TSH and T4, significantly decreased within GH (all P < 0.017). PRL significantly increased and T4 significantly decreased compared with C (both P < 0.05). The findings of this study suggest that short term use of rhGH has beneficial effects on mental state in individuals who were previous abusers of AAS and appeared to have a beneficial effect on cardiovascular risk markers associated with adverse mental health.

KW - anxiety

KW - body composition

KW - cardiovascular

KW - depression

KW - psychology

KW - insulin-like growth factor-I

U2 - 10.2174/156720207779940699

DO - 10.2174/156720207779940699

M3 - Article

VL - 4

SP - 9

EP - 18

JO - Current Neurovascular Research

JF - Current Neurovascular Research

SN - 1567-2026

IS - 1

ER -